Top

Published in:

01-10-2020 | Benign Prostatic Hypertrophy | Original Article

Immunomodulatory effect of diallyl sulfide on experimentally-induced benign prostate hyperplasia via the suppression of CD4+T/IL-17 and TGF-β1/ERK pathways

Authors: Eman M. Elbaz, Hebat Allah A. Amin, Ahmed S. Kamel, Sherehan M. Ibrahim, Hebatullah S. Helmy

Published in: Inflammopharmacology | Issue 5/2020

Abstract

Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate common in older men. Diallyl sulfide (DAS), a major component of garlic, has been reported to possess antioxidant, anti-inflammatory, and antiproliferative effects. However, the underlying protective immunomodulatory mechanism of DAS on BPH remains vague. Herein, experimental BPH was induced in rats by daily subcutaneous injection of testosterone propionate (TP) (3 mg/kg, s.c.) for 4 weeks. In parallel, finasteride (Fin) (5 mg/kg, p.o) or DAS (50 mg/kg, p.o.) was administered orally during BPH induction. TP-induced histological alterations and the immune-inflammatory cascade. On the other hand, DAS or Fin administration alleviated all abnormalities induced testosterone. Fin and DAS administration markedly reduced prostate weight by 53% with Fin, and by 60% with DAS. Moreover, serum testosterone and DHT were reduced by 55% and 52%, respectively, with Fin and by 68% and 75%, respectively, with DAS, in concordance with decreased protein expression of androgen receptor (AR), and prostate-specific antigen (PSA). Furthermore, both regime lessen immune-inflammatory milieu, as evidenced by decrease CD4+ T-cells protein expression and associated inflammatory cytokines. Concomitantly, Fin and DAS exhibited marked mitigation in insulin-like growth factor-1 (IGF-1), transforming growth factor-beta1 (TGF-β1), and phosphorylated extracellular signal-regulated kinase (ERK1/2) signaling. Besides alleviating oxidative stress by 53% and 68% in prostatic MDA and by 27% and 7% in prostatic iNOS with Fin and DAS, respectively. In conclusion, this work highlighted a potential therapeutic approach of DAS as a dietary preventive agent against BPH via its anti-inflammatory and immunomodulatory effect along with suppression of the ERK pathway.

Afdal A, Darwin E, Yanwirasti Y, Hamid R (2019) The expression of transforming growth factor beta-1 and interleukin-6 on human prostate: prostate hyperplasia and prostate cancer. Open Access Maced J Med Sci 7:1905–1910. https://doi.org/10.3889/oamjms.2019.548CrossRefPubMedPubMedCentral

Altavilla D, Minutoli L, Polito F et al (2012) Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. Br J Pharmacol 167:95–108. https://doi.org/10.1111/j.1476-5381.2012.01969.xCrossRefPubMedPubMedCentral

Ammar AE, Esmat A, Hassona MDH et al (2015) The effect of pomegranate fruit extract on testosterone-induced BPH in rats. Prostate 75:679–692. https://doi.org/10.1002/pros.22951CrossRefPubMed

Andriole G, Bruchovsky N, Chung LWK et al (2004) Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 172:1399–1403. https://doi.org/10.1097/01.JU.0000139539.94828.29CrossRefPubMed

Arunkumar R, Sharmila G, Elumalai P et al (2012) Effect of diallyl disulfide on insulin-like growth factor signaling molecules involved in cell survival and proliferation of human prostate cancer cells in vitro and in silico approach through docking analysis. Phytomedicine 19:912–923. https://doi.org/10.1016/j.phymed.2012.04.009CrossRefPubMed

Atawia RT, Tadros MG, Khalifa AE et al (2013) Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats. Toxicol Lett 219:160–169. https://doi.org/10.1016/j.toxlet.2013.03.002CrossRefPubMed

Baltaci S, Orhan D, Gögüs Ç et al (2001) Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int 88:100–103. https://doi.org/10.1046/j.1464-410x.2001.02231.xCrossRefPubMed

Bettelli E, Carrier Y, Gao W et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238. https://doi.org/10.1038/nature04753CrossRefPubMed

Chang H-P, Chen Y-H (2005) Differential effects of organosulfur compounds from garlic oil on nitric oxide and prostaglandin E2 in stimulated macrophages. Nutrition 21:530–536. https://doi.org/10.1016/j.nut.2004.07.018CrossRefPubMed

Chang H-P, Huang S-Y, Chen Y-H (2005) Modulation of cytokine secretion by garlic oil derivatives is associated with suppressed nitric oxide production in stimulated macrophages. J Agric Food Chem 53:2530–2534. https://doi.org/10.1021/jf048601nCrossRefPubMed

Chen W, Qi J, Feng F et al (2014) Neuroprotective effect of allicin against traumatic brain injury via Akt/endothelial nitric oxide synthase pathway-mediated anti-inflammatory and anti-oxidative activities. Neurochem Int 68:28–37. https://doi.org/10.1016/j.neuint.2014.01.015CrossRefPubMed

Chughtai B, Lee R, Te A, Kaplan S (2011) Role of inflammation in benign prostatic hyperplasia. Rev Urol 13:147–150. https://doi.org/10.3909/riu0535CrossRefPubMedPubMedCentral

Chun JY, Nadiminty N, Dutt S et al (2009) Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 15:4815–4822. https://doi.org/10.1158/1078-0432.CCR-09-0640CrossRefPubMedPubMedCentral

Culig Z, Hobisch A, Cronauer MV et al (1996) Regulation of prostatic growth and function by peptide growth factors. Prostate 28:392–405. https://doi.org/10.1002/(SICI)1097-0045(199606)28:6<392:AID-PROS9>3.0.CO;2-CCrossRefPubMed

Culig Z, Puhr M (2012) Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 360:52–58. https://doi.org/10.1016/j.mce.2011.05.033CrossRefPubMedPubMedCentral

Davis SR (2005) An overview of the antifungal properties of allicin and its breakdown products—the possibility of a safe and effective antifungal prophylactic. Mycoses 48:95–100. https://doi.org/10.1111/j.1439-0507.2004.01076.xCrossRefPubMed

Durak I, Yilmaz E, Devrim E et al (2003) Consumption of aqueous garlic extract leads to significant improvement in patients with benign prostate hyperplasia and prostate cancer. Nutr Res 23:199–204. https://doi.org/10.1016/S0271-5317(02)00495-5CrossRef

Fano D, Vásquez-Velásquez C, Gonzales-Castañeda C et al (2017) N-Butanol and aqueous fractions of red maca methanolic extract exerts opposite effects on androgen and oestrogens receptors (alpha and beta) in rats with testosterone-induced benign prostatic hyperplasia. Evid Based Complement Altern Med. https://doi.org/10.1155/2017/9124240CrossRef

Ficarra V, Rossanese M, Zazzara M et al (2014) The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep 15:463. https://doi.org/10.1007/s11934-014-0463-9CrossRefPubMed

Gandaglia G, Briganti A, Gontero P et al (2013) The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 112:432–441. https://doi.org/10.1111/bju.12118CrossRefPubMed

Gao H, Ouyang X, Banach-Petrosky WA et al (2006) Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 103:14477–14482. https://doi.org/10.1073/pnas.0606836103CrossRefPubMedPubMedCentral

Gao W, Bohl CE, Dalton JT (2005) Chemistry and structural biology of androgen receptor. Chem Rev 105:3352–3370. https://doi.org/10.1021/cr020456uCrossRefPubMedPubMedCentral

Gradini R, Realacci M, Ginepri A et al (1999) Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 189:224–229. https://doi.org/10.1002/(SICI)1096-9896(199910)189:2<224:AID-PATH422>3.0.CO;2-KCrossRefPubMed

Habib FK, Chisholm GD (1991) The role of growth factors in the human prostate. Scand J Urol Nephrol Suppl 138:53–58PubMed

Hall A, Troupin A, Londono-Renteria B, Colpitts T (2017) Garlic organosulfur compounds reduce inflammation and oxidative stress during dengue virus infection. Viruses 9:159. https://doi.org/10.3390/v9070159CrossRefPubMedCentral

Hardik S, Hardik M, Deepti J, Ghanashyam P (2014) Pharmacological investigation of an ayurvedic formulation on testosterone propionate-induced benign prostatic hyperplasia rats. J Exp Integr Med 4:131. https://doi.org/10.5455/jeim.280314.or.099CrossRef

Ho C-Y, Cheng Y-T, Chau C-F, Yen G-C (2012) Effect of diallyl sulfide on in vitro and in vivo Nrf2-mediated pulmonic antioxidant enzyme expression via activation ERK/p38 signaling pathway. J Agric Food Chem 60:100–107. https://doi.org/10.1021/jf203800dCrossRefPubMed

Ho CY, Lu CC, Jhang JJ, Yen GC (2017) Diallyl sulfide attenuates transforming growth factor-β-stimulated pulmonary fibrosis through Nrf2 activation in lung MRC-5 fibroblast. J Funct Foods 28:314–320. https://doi.org/10.1016/j.jff.2016.10.025CrossRef

Iciek M, Kwiecień I, Włodek L (2009) Biological properties of garlic and garlic-derived organosulfur compounds. Environ Mol Mutagen 50:247–265. https://doi.org/10.1002/em.20474CrossRefPubMed

Izumi K, Mizokami A, Lin W-J et al (2013) Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol 182:1942–1949. https://doi.org/10.1016/j.ajpath.2013.02.028CrossRefPubMedPubMedCentral

Kalayarasan S, Sriram N, Sudhandiran G (2008) Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-κB, TNF-α and IL-1β. Life Sci 82:1142–1153. https://doi.org/10.1016/j.lfs.2008.03.018CrossRefPubMed

Kantah M, Singh B, Sweed H et al (2017) Beneficial effect of a multifunctional polyphytocompound in experimental prostatic hyperplasia in rats. Clin Pharmacol Biopharm 6:1–7. https://doi.org/10.4172/2167-065X.1000169CrossRef

Karmakar S, Banik NL, Patel SJ, Ray SK (2007) Garlic compounds induced calpain and intrinsic caspase cascade for apoptosis in human malignant neuroblastoma SH-SY5Y cells. Apoptosis 12:671–684. https://doi.org/10.1007/s10495-006-0024-xCrossRefPubMed

Khurana N, Sikka S (2018) Targeting crosstalk between Nrf-2, NF-κB and androgen receptor signaling in prostate cancer. Cancers (Basel) 10:352. https://doi.org/10.3390/cancers10100352CrossRef

Kim S-H, Lee I-C, Ko J-W et al (2016) Mechanism of protection by diallyl disulfide against cyclophosphamide-induced spermatotoxicity and oxidative stress in rats. Mol Cell Toxicol 12:301–312. https://doi.org/10.1007/s13273-016-0035-9CrossRef

Kim SK, Seok H, Park HJ et al (2015) Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model. BMC Complement Altern Med 15:380. https://doi.org/10.1186/s12906-015-0825-yCrossRefPubMedPubMedCentral

Kleinert H, Schwarz PM, Förstermann U (2003) Regulation of the expression of inducible nitric oxide synthase. Biol Chem 384:1343–1364. https://doi.org/10.1515/BC.2003.152CrossRefPubMed

Klyushnenkova EN, Ponniah S, Rodriguez A et al (2004) CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. J Immunother 27:136–146. https://doi.org/10.1097/00002371-200403000-00007CrossRefPubMed

Ko JW, Jeong SH, Kwon HJ et al (2018) Preventive effect of garlic oil and its organosulfur component diallyl-disulfide on cigarette smoke-induced airway inflammation in mice. Nutrients 10:1–12. https://doi.org/10.3390/nu10111659CrossRef

Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51:1202–1216. https://doi.org/10.1016/j.eururo.2006.12.011CrossRefPubMed

Krušlin B, Tomas D, Džombeta T et al (2017) Inflammation in prostatic hyperplasia and carcinoma-basic scientific approach. Front Oncol 7:77. https://doi.org/10.3389/fonc.2017.00077CrossRefPubMedPubMedCentral

Kuttan G (2000) Immunomodulatory effect of some naturally occuring sulphur-containing compounds. J Ethnopharmacol 72:93–99. https://doi.org/10.1016/S0378-8741(00)00211-7CrossRefPubMed

Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T (2017) The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediat Inflamm. https://doi.org/10.1155/2017/3908061CrossRef

Li C, Lun W, Zhao X et al (2015) Allicin alleviates inflammation of trinitrobenzenesulfonic acid-induced rats and suppresses P38 and JNK pathways in caco-2 cells. Mediat Inflamm 2015:1–11. https://doi.org/10.1155/2015/434692CrossRef

Madersbacher S, Culig Z, Sampson N, Culig Z (2019) Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology 65:458–464. https://doi.org/10.1159/000496289CrossRefPubMed

Marberger M (2013) Medical management of lower urinary tract symptoms in men with benign prostatic enlargement. Adv Ther 30:309–319. https://doi.org/10.1007/s12325-013-0022-7CrossRefPubMed

Moutia M, Seghrouchni F, Abouelazz O et al (2016) Allium sativum L. regulates in vitro IL-17 gene expression in human peripheral blood mononuclear cells. BMC Complement Altern Med 16:377. https://doi.org/10.1186/s12906-016-1365-9CrossRefPubMedPubMedCentral

Pace G, Di Massimo C, De Amicis D et al (2011) Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol 37:617–622. https://doi.org/10.1590/S1677-55382011000500008CrossRefPubMed

Paolone DR (2010) Benign prostatic hyperplasia. Clin Geriatr Med 26:223–239. https://doi.org/10.1016/j.cger.2010.02.010CrossRefPubMed

Papatsoris AG, Papavassiliou AG (2001) Molecular “palpation” of BPH: a tale of MAPK signalling? Trends Mol Med 7:288–292. https://doi.org/10.1016/S1471-4914(01)02015-9CrossRefPubMed

Paulis G (2018) Inflammatory mechanisms and oxidative stress in prostatitis: the possible role of antioxidant therapy. Res Rep Urol 10:75–87. https://doi.org/10.2147/RRU.S170400CrossRefPubMedPubMedCentral

Penna G, Fibbi B, Amuchastegui S et al (2009) Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 182:4056–4064. https://doi.org/10.4049/jimmunol.0801875CrossRefPubMed

Penna G, Mondaini N, Amuchastegui S et al (2007) Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 51:524–533. https://doi.org/10.1016/j.eururo.2006.07.016CrossRefPubMed

Peterziel H, Mink S, Schonert A et al (1999) Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 18:6322–6329. https://doi.org/10.1038/sj.onc.1203032CrossRefPubMed

Prasad S, Kalra N, Shukla Y (2006) Modulatory effects of diallyl sulfide against testosterone-induced oxidative stress in Swiss albino mice. Asian J Androl 8:719–723. https://doi.org/10.1111/j.1745-7262.2006.00201.xCrossRefPubMed

Rao PSS, Midde NM, Miller DD et al (2015) Diallyl sulfide: potential use in novel therapeutic interventions in alcohol, drugs, and disease mediated cellular toxicity by targeting cytochrome P450 2E1. Curr Drug Metab 16:486–503. https://doi.org/10.2174/1389200216666150812123554CrossRefPubMedPubMedCentral

Sayed RH, Saad MA, El-Sahar AE (2016) Dapoxetine attenuates testosterone-induced prostatic hyperplasia in rats by the regulation of inflammatory and apoptotic proteins. Toxicol Appl Pharmacol 311:52–60. https://doi.org/10.1016/j.taap.2016.09.024CrossRefPubMed

Schäfer G, Kaschula C (2014) The Immunomodulation and anti-inflammatory effects of garlic organosulfur compounds in cancer chemoprevention. Anticancer Agents Med Chem 14:233–240. https://doi.org/10.2174/18715206113136660370CrossRefPubMedPubMedCentral

Schalken JA (2004) Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. BJU Int 93:5–9CrossRefPubMed

Scott Lucia M, Lambert JR (2008) Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep 9:272–278. https://doi.org/10.1007/s11934-008-0048-6CrossRefPubMed

Sebastianelli A, Gacci M (2018) Current status of the relationship between metabolic syndrome and lower urinary tract symptoms. Eur Urol Focus 4:25–27. https://doi.org/10.1016/j.euf.2018.03.007CrossRefPubMed

Stan SD, Singh SV (2009) Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells. Clin Cancer Res 15:4895–4903. https://doi.org/10.1158/1078-0432.CCR-09-0512CrossRefPubMedPubMedCentral

Steiner GE, Newman ME, Paikl D et al (2003) Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56:171–182. https://doi.org/10.1002/pros.10238CrossRefPubMed

Sun C, Peng Y, Wu Y et al (2020) The effect of Metapanax delavayi leaf extract on testosterone-induced benign prostatic hyperplasia in rats. J Funct Foods. https://doi.org/10.1016/j.jff.2020.103797CrossRef

Thomson M, Ali M (2003) Garlic [Allium sativum]: a review of its potential use as an anti-cancer agent. Curr Cancer Drug Targets 3:67–81. https://doi.org/10.2174/1568009033333736CrossRefPubMed

Vásquez-Velásquez C, Gasco M, Fano-Sizgorich D, Gonzales GF (2020) Inflammatory pathway employed by Red Maca to treat induced benign prostatic hyperplasia in rats. Andrologia 52:1–8. https://doi.org/10.1111/and.13516CrossRef

Veldhoen M, Hocking RJ, Atkins CJ et al (2006) TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179–189. https://doi.org/10.1016/j.immuni.2006.01.001CrossRefPubMed

Vyas BA, Desai NY, Patel PK et al (2013) Effect of Boerhaavia diffusa in experimental prostatic hyperplasia in rats. Indian J Pharmacol 45:264–269. https://doi.org/10.4103/0253-7613.111946CrossRefPubMedPubMedCentral

Wang C, Luo F, Zhou Y et al (2016) The therapeutic effects of docosahexaenoic acid on oestrogen/androgen-induced benign prostatic hyperplasia in rats. Exp Cell Res 345:125–133. https://doi.org/10.1016/j.yexcr.2015.03.026CrossRefPubMed

Wang H-C, Pao J, Lin S-Y, Sheen L-Y (2012) Molecular mechanisms of garlic-derived allyl sulfides in the inhibition of skin cancer progression. Ann N Y Acad Sci 1271:44–52. https://doi.org/10.1111/j.1749-6632.2012.06743.xCrossRefPubMedPubMedCentral

Xu C, Mathews AE, Rodrigues C et al (2018) Aged garlic extract supplementation modifies inflammation and immunity of adults with obesity: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr ESPEN 24:148–155. https://doi.org/10.1016/j.clnesp.2017.11.010CrossRefPubMed

Xu H, Fu S, Chen Y et al (2017) Oxytocin: its role in benign prostatic hyperplasia via the ERK pathway. Clin Sci 131:595–607. https://doi.org/10.1042/CS20170030CrossRef

Yang X, Yuan L, Xiong C et al (2014) Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative. J Ethnopharmacol 157:105–113. https://doi.org/10.1016/j.jep.2014.09.025CrossRefPubMed

Yi L, Su Q (2013) Molecular mechanisms for the anti-cancer effects of diallyl disulfide. Food Chem Toxicol 57:362–370. https://doi.org/10.1016/j.fct.2013.04.001CrossRefPubMed

Youn DH, Park J, Kim HL et al (2017) Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase. Oncotarget 8:9500–9512. https://doi.org/10.18632/oncotarget.13430CrossRefPubMed

Zhang P, Noordine M-L, Cherbuy C et al (2006) Different activation patterns of rat xenobiotic metabolism genes by two constituents of garlic. Carcinogenesis 27:2090–2095. https://doi.org/10.1093/carcin/bgl064CrossRefPubMed

Zhang Z, Duan L, Du X et al (2008) The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK. Prostate 68:508–516. https://doi.org/10.1002/pros.20722CrossRefPubMed

Zou X, Liang J, Sun J et al (2016) Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway. J Pharmacol Sci 131:233–240. https://doi.org/10.1016/j.jphs.2016.04.017CrossRefPubMed

Title: Immunomodulatory effect of diallyl sulfide on experimentally-induced benign prostate hyperplasia via the suppression of CD4+T/IL-17 and TGF-β1/ERK pathways
Authors: Eman M. Elbaz
Hebat Allah A. Amin
Ahmed S. Kamel
Sherehan M. Ibrahim
Hebatullah S. Helmy
Publication date: 01-10-2020
Publisher: Springer International Publishing
Keywords: Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Finasteride
Testosterone
Stanolone
Androgens
Published in: Inflammopharmacology / Issue 5/2020
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-020-00743-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immunomodulatory effect of diallyl sulfide on experimentally-induced benign prostate hyperplasia via the suppression of CD4+T/IL-17 and TGF-β1/ERK pathways

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

New synthetic coumarinolignans as attenuators of pro-inflammatory cytokines in LPS-induced sepsis and carrageenan-induced paw oedema models

Perindopril ameliorates experimental Alzheimer’s disease progression: role of amyloid β degradation, central estrogen receptor and hyperlipidemic-lipid raft signaling

Metformin ameliorates animal models of dermatitis

Better outcomes for patients with gout

The advances of methotrexate resistance in rheumatoid arthritis

Apixaban exhibits anti-arthritic effects by inhibiting activated factor X-mediated JAK2/STAT3 and MAPK phosphorylation pathways